A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.
MEK-1/2
hypothalamic glioma
optic pathway glioma
pediatric low-grade glioma
selumetinib
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
01 10 2021
01 10 2021
Historique:
pubmed:
26
2
2021
medline:
6
10
2021
entrez:
25
2
2021
Statut:
ppublish
Résumé
Pediatric low-grade gliomas (pLGGs) are the most common childhood brain tumor. Progression-free survival (PFS) is much lower than overall survival, emphasizing the need for alternative treatments. Sporadic (without neurofibromatosis type 1) optic pathway and hypothalamic gliomas (OPHGs) are often multiply recurrent and cause significant visual deficits. Recently, there has been a prioritization of functional outcomes. We present results from children with recurrent/progressive OPHGs treated on a PBTC (Pediatric Brain Tumor Consortium) phase II trial evaluating efficacy of selumetinib (AZD6244, ARRY-142886) a MEK-1/2 inhibitor. Stratum 4 of PBTC-029 included patients with sporadic recurrent/progressive OPHGs treated with selumetinib at the recommended phase II dose (25mg/m2/dose BID) for a maximum of 26 courses. Twenty-five eligible and evaluable patients were enrolled with a median of 4 (1-11) previous therapies. Six of 25 (24%) had partial response, 14/25 (56%) had stable disease, and 5 (20%) had progressive disease while on treatment. The median treatment courses were 26 (2-26); 14/25 patients completed all 26 courses. Two-year PFS was 78 ± 8.5%. Nineteen of 25 patients were evaluable for visual acuity which improved in 4/19 patients (21%), was stable in 13/19 (68%), and worsened in 2/19 (11%). Five of 19 patients (26%) had improved visual fields and 14/19 (74%) were stable. The most common toxicities were grade 1/2 CPK elevation, anemia, diarrhea, headache, nausea/emesis, fatigue, AST and ALT increase, hypoalbuminemia, and rash. Selumetinib was tolerable and led to responses and prolonged disease stability in children with recurrent/progressive OPHGs based upon radiographic response, PFS, and visual outcomes.
Sections du résumé
BACKGROUND
Pediatric low-grade gliomas (pLGGs) are the most common childhood brain tumor. Progression-free survival (PFS) is much lower than overall survival, emphasizing the need for alternative treatments. Sporadic (without neurofibromatosis type 1) optic pathway and hypothalamic gliomas (OPHGs) are often multiply recurrent and cause significant visual deficits. Recently, there has been a prioritization of functional outcomes.
METHODS
We present results from children with recurrent/progressive OPHGs treated on a PBTC (Pediatric Brain Tumor Consortium) phase II trial evaluating efficacy of selumetinib (AZD6244, ARRY-142886) a MEK-1/2 inhibitor. Stratum 4 of PBTC-029 included patients with sporadic recurrent/progressive OPHGs treated with selumetinib at the recommended phase II dose (25mg/m2/dose BID) for a maximum of 26 courses.
RESULTS
Twenty-five eligible and evaluable patients were enrolled with a median of 4 (1-11) previous therapies. Six of 25 (24%) had partial response, 14/25 (56%) had stable disease, and 5 (20%) had progressive disease while on treatment. The median treatment courses were 26 (2-26); 14/25 patients completed all 26 courses. Two-year PFS was 78 ± 8.5%. Nineteen of 25 patients were evaluable for visual acuity which improved in 4/19 patients (21%), was stable in 13/19 (68%), and worsened in 2/19 (11%). Five of 19 patients (26%) had improved visual fields and 14/19 (74%) were stable. The most common toxicities were grade 1/2 CPK elevation, anemia, diarrhea, headache, nausea/emesis, fatigue, AST and ALT increase, hypoalbuminemia, and rash.
CONCLUSIONS
Selumetinib was tolerable and led to responses and prolonged disease stability in children with recurrent/progressive OPHGs based upon radiographic response, PFS, and visual outcomes.
Identifiants
pubmed: 33631016
pii: 6149924
doi: 10.1093/neuonc/noab047
pmc: PMC8485450
doi:
Substances chimiques
AZD 6244
0
Benzimidazoles
0
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1777-1788Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : UM1 CA081457
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Pediatr Hematol Oncol. 2020 May;42(4):e248-e250
pubmed: 30676433
Neuro Oncol. 2018 Jan 22;20(2):160-173
pubmed: 29016845
Neurology. 2013 Nov 19;81(21 Suppl 1):S15-24
pubmed: 24249802
Pediatr Neurol. 2003 Apr;28(4):262-70
pubmed: 12849878
Cancer Cell. 2020 Apr 13;37(4):569-583.e5
pubmed: 32289278
CNS Oncol. 2017 Oct;6(4):291-296
pubmed: 28984141
J Neurooncol. 2016 Aug;129(1):173-8
pubmed: 27311725
J Clin Oncol. 2012 Jul 20;30(21):2641-7
pubmed: 22665535
Cancer. 1995 Feb 15;75(4):1051-9
pubmed: 7842408
J Child Neurol. 2016 Feb;31(2):237-54
pubmed: 26045296
J Clin Oncol. 2002 Jul 1;20(13):2951-8
pubmed: 12089224
Neuro Oncol. 2014 Jan;16(2):310-7
pubmed: 24311632
J Pediatr Hematol Oncol. 2021 May 1;43(4):e550-e553
pubmed: 32520842
Neuro Oncol. 2017 Aug 1;19(8):1135-1144
pubmed: 28339824
Lancet Oncol. 2019 Jul;20(7):1011-1022
pubmed: 31151904
Pediatr Blood Cancer. 2014 Jul;61(7):1173-9
pubmed: 24482038
J Neurooncol. 2020 Sep;149(2):253-262
pubmed: 32780261
J Clin Oncol. 2012 Apr 20;30(12):1358-63
pubmed: 22393086
Lancet Oncol. 2020 Jun;21(6):e305-e316
pubmed: 32502457
Br J Ophthalmol. 2018 Oct;102(10):1367-1371
pubmed: 29343527
J Clin Oncol. 2017 Jul 20;35(21):2370-2377
pubmed: 28640698
Neuro Oncol. 2019 Nov 1;21(Suppl 5):v1-v100
pubmed: 31675094
J Neuropathol Exp Neurol. 2012 Sep;71(9):789-94
pubmed: 22892521
Neuro Oncol. 2020 Jun 9;22(6):773-784
pubmed: 32055852
Neuro Oncol. 2017 Jun 1;19(6):750-761
pubmed: 27683733
Arch Ophthalmol. 2001 Apr;119(4):516-29
pubmed: 11296017
J Child Neurol. 2003 Jul;18(7):471-8
pubmed: 12940652
Eur J Cancer. 2010 Aug;46(12):2253-9
pubmed: 20400294
Curr Opin Pediatr. 2019 Feb;31(1):21-27
pubmed: 30531227
Cancer. 2016 Jun 15;122(12):1928-36
pubmed: 27061921
Neuro Oncol. 2000 Oct;2(4):213-20
pubmed: 11265230
BMC Cancer. 2019 Dec 27;19(1):1250
pubmed: 31881853
J Neurosurg Pediatr. 2017 Mar;19(3):319-324
pubmed: 28009226
J Clin Oncol. 2016 Oct 10;34(29):3537-3543
pubmed: 27573663